SCHEMBL4716268

SCHEMBL4716268

O=c1ccc2c(ccn2S(=O)(=O)c2ccccc2)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 17/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
HTT P42858 1/20 0.53
MET P08581 1/20 0.47
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
BRD4 O60885 1/20 0.44
CYP3A4 P08684 1/20 0.44
DRD3 P35462 2/20 0.42
DRD2 P14416 1/20 0.42
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR1F P30939 1/20 0.42
HTR7 P34969 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649362 0.70 DDB1 (0.59) MEN1KMT2ALMNAMETL3MBTL1
SCHEMBL429849 0.69 HTR6 (1.00) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL29558135 0.69 HTR6 (1.00) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL3238869 0.69 HTR6 (0.50) HTR6MEN1KMT2AALDH1A1LMNA
Hydrochloric Acid SCHEMBL28794299 0.68 HTR6 (0.96) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL4714520 0.68 HTR6 (0.55) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL29744143 0.67 HTR6 (0.65) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL3260344 0.67 HTR6 (0.65) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL4063446 0.66 CHRM1 (0.50) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL2510832 0.66 HTR6 (0.68) HTR6MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 HTR6 2747/4885MEN1 4819/4885KMT2A 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.